Alirocumab inhibits atherosclerosis, improves the plaque morphology, and enhances the effects of a statin[S]

Autor: Susan Kühnast, José W.A. van der Hoorn, Elsbet J. Pieterman, Anita M. van den Hoek, William J. Sasiela, Viktoria Gusarova, Anusch Peyman, Hans-Ludwig Schäfer, Uwe Schwahn, J. Wouter Jukema, Hans M.G. Princen

Publikováno v: Journal of Lipid Research, Vol 55, Iss 10, Pp 2103-2112 (2014)

Proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibition is a potential novel strategy for treatment of CVD. Alirocumab is a fully human PCSK9 monoclonal antibody in phase 3 clinical development. We evaluated the antiatherogenic potential of

Externí odkaz: https://doaj.org/article/53e1f0f319af41358683cedf9dce15c4

The AT04A vaccine against proprotein convertase subtilisin/kexin type 9 reduces total cholesterol, vascular inflammation, and atherosclerosis in APOE*3Leiden.CETP mice

Aims: Proprotein convertase subtilisin/kexin type 9 (PCSK9) has emerged as a promising therapeutic target for the treatment of hypercholesterolaemia and atherosclerosis. PCSK9 binds to the low density lipoprotein receptor and enhances its degradation

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=dris___00893::19c3ae399b548178e9e0bf0b24ce9ccc
http://resolver.tudelft.nl/uuid:31d3da74-88bf-479b-a516-90503763d0fe

Alirocumab inhibits atherosclerosis, improves the plaque morphology, and enhances the effects of a statin

Autor: Anusch Peyman, Elsbet J. Pieterman, Hans-Ludwig Schäfer, Anita M. van den Hoek, Uwe Schwahn, Susan Kühnast, José W.A. van der Hoorn, Viktoria Gusarova, William J. Sasiela, J. Wouter Jukema, Hans M.G. Princen

Publikováno v: Journal of Lipid Research, 10, 55, 2103-2112
Journal of Lipid Research, 55(10), 2103-2112
Journal of Lipid Research, Vol 55, Iss 10, Pp 2103-2112 (2014)
Journal of Lipid Research

Proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibition is a potential novel strategy for treatment of CVD. Alirocumab is a fully human PCSK9 monoclonal antibody in phase 3 clinical development. We evaluated the antiatherogenic potential of

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::0f7b3416033f6aa49c622e6e0617ffe8
http://resolver.tudelft.nl/uuid:17ce4754-8fa8-4e08-b529-0e07e5ec7fb3

Innovative pharmaceutical interventions in cardiovascular disease: Focusing on the contribution of non-HDL-C/LDL-C-lowering versus HDL-C-raisingA systematic review and meta-analysis of relevant preclinical studies and clinical trials

Non-HDL-cholesterol is well recognised as a primary causal risk factor in cardiovascular disease. However, despite consistent epidemiological evidence for an inverse association between HDL-C and coronary heart disease, clinical trials aimed at raisi

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=dris___00893::865732688cb9f04dca435ba80a1353bc
http://resolver.tudelft.nl/uuid:80d5ce79-8fee-40f1-a1eb-828bf010c239

Aliskiren inhibits atherosclerosis development and improves plaque stability in APOEM*3Leiden.CETP transgenic mice with or without treatment with atorvastatin

Autor: Gene Liau, Hans M.G. Princen, José W.A. van der Hoorn, Anita M. van den Hoek, J. Wouter Jukema, Louis M. Havekes, Susan Kühnast

Publikováno v: Journal of Hypertension, 1, 30, 107-116
Journal of Hypertension, 30(1), 107-116
Journal of Hypertension, 30(1), 107-16

Objective: Aliskiren is the first commercially available, orally active, direct renin inhibitor approved to treat hypertension. The renin-angiotensin system has been shown to be a significant contributor to the development of hypercholesterolemia-ind

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::bcbe2be8b56e63327af1e3e80f95671b
https://hdl.handle.net/1887/111167